Anaphylaxis rates associated with COVID-19 vaccines are comparable to those of other vaccines.
Vaccine
; 40(2): 183-186, 2022 01 21.
Article
in English
| MEDLINE | ID: covidwho-1537111
ABSTRACT
We retrieved data on 8940 anaphylaxis cases post-COVID-19 vaccination from the US Vaccine Adverse Event Reporting System and the European EudraVigilance from week 52/2020 through week 31/2021 and compared them with those of other vaccines. Overall, 837,830,000 COVID-19 vaccine doses were delivered in the US and Europe during the study period, for which the vaccine name was known. The mean anaphylaxis rate was estimated at 10.67 cases per 106 doses of COVID-19 vaccines (range 7.99-19.39 cases per 106 doses depending on the vaccine). COVID-19 vaccines ranked fifth in reported anaphylaxis rates, behind rabies, tick-borne encephalitis, measles-mumps-rubella-varicella, and human papillomavirus vaccines (70.77, 20, 19.8, and 13.65 cases per 106 vaccine doses, respectively). COVID-19 vaccines are within the range of anaphylaxis rates reported across several common vaccines in these two passive reporting systems. These data should be communicated to reassure the general population about the safety profile of COVID-19 vaccines.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19
/
Anaphylaxis
Type of study:
Observational study
Topics:
Long Covid
/
Vaccines
Limits:
Humans
/
Infant
Language:
English
Journal:
Vaccine
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS